Merus’ zenocutuzumab is nearing FDA approval, and petosemtamab shows promise. Learn why MRUS stock could rise as the company ...

In a report released today, Charles Zhu from LifeSci Capital maintained a Buy rating on Merus (MRUS – Research Report), with a price ...

Andrew Berens, an analyst from Leerink Partners, maintained the Buy rating on Merus (MRUS – Research Report). The associated price target ...

Mirae Asset Global Investments Co. Ltd. increased its position in shares of Merus (NASDAQ:MRUS – Free Report) by 24.7% in the 3rd quarter, Holdings Channel.com reports. The fund owned 2,467 shares of ...

Idaho – which finished 11-21, with a 5-13 mark in the Big Sky – won half of its preseason games before coming up with some ...

GET MORE AI-GENERATED SIGNALS: October 23, 2024, 07:32 am ET, BY Randall S.- Contributor| Editor: Thomas H. Kee Jr. ( Follow on LinkedIn) Short MRUS slightly under 59.06, target 51.8, stop loss @ ...

The overall quant rating is not an average of the factor grades listed. Instead, it gives greater weight to the metrics with the strongest predictive value.

Below is Validea's guru fundamental report for MERUS NV (MRUS). Of the 22 guru strategies we follow, MRUS rates highest using our P/B Growth Investor model based on the published strategy of ...

There are no important events for this country at this time. Select "All" to see top events in other countries or view all events.